title: Ulinastatin- and thymosin α1-based immunomodulatory strategy for sepsis: A meta-analysis.
abstract: OBJECTIVE
  This meta-analysis was performed to evaluate the efficacy of ulinastatin (UTI) and thymosin α1 (Tα1) based immunomodulatory strategy in sepsis patients.
  
  
  METHODS
  A systematic search was made of MEDLINE, Cochrane, ISI Web of Science and SCOPUS databases. Randomized clinical trials on treatment of sepsis with the combination of ulinastatin and Tα1, compared with placebo, were reviewed. Studies were pooled to relative risk (RR) and weighted mean differences (WMD), with 95% confidence interval (CI).
  
  
  RESULTS
  Six trials (enrolling 915 participants) met the inclusion criteria. Compared with placebo, the combination of ulinastatin and Tα1 presented significant effects on 28-day all-cause mortality (RR 0.67; 95% CI 0.57 to 0.80), 90-day all-cause mortality (RR 0.75; 95% CI 0.61 to 0.93), TNF-α (WMD -73.86ng/L; 95% CI -91.00 to -56.73ng/L), IL-6 (WMD -55.04ng/L; 95% CI -61.22 to -48.85ng/L), and duration of mechanical ventilation (WMD -2.26days; 95% CI -2.79 to -1.73days).
  
  
  CONCLUSIONS
  Immunomodulatory therapy that combines ulinastatin and Tα1 significantly improves all-cause mortality, inflammatory mediators and duration of mechanical ventilation in subjects with sepsis.
authors.affiliation: Department of Respiratory and Critical Care Medicine, Shaanxi Provincial People's Hospital, Xi'an, Shaanxi 710068, PR China. Electronic address: sesory@yeah.net.
authors.forename: Dong
authors.initials: D
authors.lastname: Han
authors.affiliation: Department of Respiratory and Critical Care Medicine, Shaanxi Provincial People's Hospital, Xi'an, Shaanxi 710068, PR China.
authors.forename: Wenli
authors.initials: W
authors.lastname: Shang
authors.affiliation: Department of Respiratory and Critical Care Medicine, Shaanxi Provincial People's Hospital, Xi'an, Shaanxi 710068, PR China.
authors.forename: Guizuo
authors.initials: G
authors.lastname: Wang
authors.affiliation: Department of Respiratory and Critical Care Medicine, Shaanxi Provincial People's Hospital, Xi'an, Shaanxi 710068, PR China.
authors.forename: Li
authors.initials: L
authors.lastname: Sun
authors.affiliation: Department of Respiratory and Critical Care Medicine, The Second Affiliated Hospital of Medical College, Xi'an Jiaotong University, Xi'an, Shaanxi 710004, PR China.
authors.forename: Yingying
authors.initials: Y
authors.lastname: Zhang
authors.affiliation: Department of Respiratory and Critical Care Medicine, Shaanxi Provincial People's Hospital, Xi'an, Shaanxi 710068, PR China.
authors.forename: Hongxia
authors.initials: H
authors.lastname: Wen
authors.affiliation: Department of Respiratory and Critical Care Medicine, Shaanxi Provincial People's Hospital, Xi'an, Shaanxi 710068, PR China.
authors.forename: Lingbin
authors.initials: L
authors.lastname: Xu
mesh_terms: D006023:Glycoproteins / Q000627:therapeutic use*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D007155:Immunologic Factors / Q000627:therapeutic use*; D018805:Sepsis / Q000188:drug therapy*; D000077596:Thymalfasin; D013947:Thymosin / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D006023:Glycoproteins; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D007155:Immunologic Factors; D013947:Thymosin; C028665:urinastatin; D000077596:Thymalfasin
keywords: Meta-analysis; Sepsis; Thymosin α1; Ulinastatin